NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 174 filers reported holding NEVRO CORP in Q4 2016. The put-call ratio across all filers is 0.56 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $18,334,000 | -14.9% | 229,608 | -7.7% | 1.04% | -13.1% |
| Q1 2018 | $21,552,000 | +1.1% | 248,673 | -19.5% | 1.20% | +17.6% |
| Q4 2017 | $21,321,000 | -38.8% | 308,819 | -19.4% | 1.02% | -28.1% |
| Q3 2017 | $34,829,000 | -14.8% | 383,247 | -30.2% | 1.42% | +8.6% |
| Q2 2017 | $40,857,000 | -18.2% | 548,935 | +3.0% | 1.30% | -22.3% |
| Q1 2017 | $49,940,000 | +55.9% | 532,983 | +20.9% | 1.68% | +61.6% |
| Q4 2016 | $32,030,000 | -35.1% | 440,818 | -6.8% | 1.04% | -19.0% |
| Q3 2016 | $49,371,000 | +25.5% | 472,940 | -11.3% | 1.28% | +26.7% |
| Q2 2016 | $39,341,000 | -35.8% | 533,364 | -51.0% | 1.01% | +28.5% |
| Q1 2016 | $61,278,000 | +130.0% | 1,089,180 | +176.0% | 0.79% | +23.4% |
| Q4 2015 | $26,641,000 | +45.5% | 394,636 | +0.0% | 0.64% | +46.3% |
| Q3 2015 | $18,307,000 | -13.8% | 394,635 | -0.2% | 0.44% | -3.3% |
| Q2 2015 | $21,248,000 | +249.0% | 395,311 | +211.2% | 0.45% | +229.2% |
| Q1 2015 | $6,089,000 | – | 127,038 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
| Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
| PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
| Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
| Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
| Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
| K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
| Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
| Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
| ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |